Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER 096

Next Previous
Drug Profile

HER 096

Alternative Names: CDNF; CDNF-protein; Cerebral dopamine neurotrophic factor - Herantis Pharma; HER-096; recombinant human CDNF; rhCDNF

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma; Nanoform; Renishaw
  • Class Antidementias; Antiparkinsonians; Nerve growth factors; Neuroprotectants; Recombinant proteins
  • Mechanism of Action Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Parkinson's disease

Highest Development Phases

  • Phase I/II Parkinson's disease
  • No development reported Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for preclinical development in Parkinson's-disease in Finland (Intranasal, Spray)
  • 07 Oct 2025 Pharmacokinetics and adverse events data from a phase Ib trial in Parkinson's disease released by Herantis Pharma
  • 07 Oct 2025 Herantis Pharma plans a phase II trial for Parkinson's disease (Early stage disease) (SC, Injection) in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top